Abstract:Valentina Zanuso, 1, 2 Angelo Pirozzi, 1, 2 Rita Balsano, 2 Tiziana Pressiani, 2 Lorenza Rimassa 1, 2 1 Department of Biomedical Sciences, Humanitas University, Milan, Italy; 2 Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy Correspondence: Lorenza Rimassa, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy, Tel +39 02 82244573, Fax +39 02 82244590, Email Hepatocellular carcinoma (HCC) is one of the most common leading causes of cancer death worldwide. As most patients are diagnosed with advanced disease, systemic therapy remains the backbone of treatment. In recent years, we have witnessed the transformation of advanced HCC treatment landscapes from single-agent targeted therapies to immunotherapy combinations, with atezolizumab plus bevacizumab becoming the new first-line standard of care with an increase in overall survival, progression-free survival, and objective response rate compared to sorafenib, and a positive impact on quality of life. Although the efficacy and safety of this combination have been confirmed regardless of ethnicity, age, and etiology, only a subgroup of patients seems to benefit the most from this treatment. Currently, predictive serum and tissue biomarkers to select patients who are most likely to respond to atezolizumab plus bevacizumab are lacking. Moreover, the optimal subsequent therapy for patients who progress on first-line atezolizumab plus bevacizumab remains unknown, clinical trials are ongoing, and real-world data are needed to determine the most effective treatment sequence. Importantly, careful evaluation of bleeding risk and preservation of adequate liver function are fundamental to improve patients' prognosis, especially when subsequent treatments are administered. Keywords: HCC, immune checkpoint inhibitors, atezolizumab, bevacizumab, safety, efficacy Hepatocellular carcinoma (HCC) is a global health issue with increasing incidence and mortality worldwide. It generally emerges within a chronic liver disease condition, which includes chronic viral hepatitis (hepatitis C virus [HCV] and hepatitis B virus [HBV]), alcoholic cirrhosis, metabolic conditions (metabolic dysfunction-associated fatty liver disease [MAFLD], previously known as non-alcoholic fatty liver disease [NAFLD], metabolic dysfunction-associated steatohepatitis [MASH], previously known as non-alcoholic steatohepatitis [NASH], diabetes), and aflatoxin exposure. 1,2 Unfortunately, most patients are diagnosed with advanced disease or progress after locoregional approaches and therefore, systemic therapies represent the backbone of treatment. Systemic treatment is indicated for patients with advanced or intermediate HCC that are unsuitable for locoregional treatment and with preserved liver function. 1,3 After more than a decade of multi-kinase inhibitors (MKIs) monopoly, in 2020, the combination of atezolizumab plus bevacizumab became the new first-line standard of care, introducing immunotherapy in advanced HCC and contributing to the reshaping of HCC treatment algorithm, with an increase in survival. In this review, we will shed light on atezolizumab plus bevacizumab, starting from clinical studies that led to the approval of this combination, focusing on safety and efficacy data, and then moving to more recent exploratory analyses and real-life studies, evaluating future perspectives of HCC treatment strategies and sequential therapies. Moreover, we want to highlight the urgent need to identify predictive biomarkers to properly select patients and obtain durable clinical benefits in those who are more likely to respond, sparing adverse events in non-responders. Sorafenib, a MKI, has been the mainstay of advanced or metastatic HCC treatment since 2007. 4,5 A decade later, new targeted agents have been approved in either the first or subsequent lines. In detail, lenvatinib was found to be non-inferior to sorafenib in the first-line setting. 6 Regorafenib, cabozantinib, and ramucirumab were approved in the refractory context, with cabozantinib showing efficacy even in the third line. 7–9 Furthermore, regorafenib demonstrated efficacy in a sorafenib-tolerant population, whereas ramucirumab showed improved survival in patients with alpha-fetoprotein (AFP) levels ≥400 ng/mL at baseline. 7,9 Recently, the advent of immunotherapy has dramatically changed the first-line therapeutic scenario, resulting in a widening of treatment opportunities. In 2020, the combination of the anti-programmed death ligand-1 (PD-L1) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) bevacizumab became the new first-line standard of care, outperforming sorafenib. 10–12 S -Abstract Truncated-

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Atezolizumab with or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): an Open-Label, Multicentre, Phase 1b Study

Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis

A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.

Bevacizumab Combined with Atezolizumab or Sintilimab As Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Study.

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study

Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients

Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study

Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis

Optimal First- and Second-Line Treatment Regimens in Patients with Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma

Efficacy of Αtezolizumab-Βevacizumab in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression, the type of BCLC-C and liver disease severity

Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma

Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma.

Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.